Claim Missing Document
Check
Articles

Found 2 Documents
Search

The Effect of The ERACS Method on The Acceleration of Mobilization of Post Sectio Caesaria Patients at Academic Hospital Universitas Gadjah Mada In 2023 Krismayanti, Dewi; Haspitaningrum, Anjarsari; Risanto, Esti Utami
Academic Hospital Journal Vol 6, No 1 (2024)
Publisher : Rumah Sakit Akademik Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ahj.v6i1.94807

Abstract

Background: ERACS (Enhanced Recovery After Caesarian Surgery) is a fast programrecovery after a Caesarean section in the form of a series of care starting from preoperativepreparation, intraoperative and post-operative care until the patient is discharged. InIndonesia itself, the implementation of the ERACS protocol began to be implemented in2019. UGM Academic Hospital, the ERACS method is still a new service from the MaternalPerinatal Installation and will start running in November 2022. This research aims todetermine the difference in maternal mobilization time post Sectio Caesaria with the ERACSmethod and mobilization of mothers post non-eracs SC at UGM Academic Hospital in 2023.This research is a quantitative research using a quasi-experimental method with anonequivalent posttest control group design. The research was conducted at the UGMAcademic Hospital in April - September 2023. The sampling technique was accidentalsampling. The research results showed that the average mobilization of post-Sc patientsusing the ERACS method was 13.1 hours and the average mobilization of non-ERACS post-Scpatients was 33.7 hours. From the results of the analysis of 54 respondents using theIndependent Sample Test, it shows a value of 0.000. So H0 is rejected and Ha is accepted.Conclusion: there is an effect of giving the ERACS method by accelerating the mobilizationof women giving birth post sc.Keywords: Sectio Caesaria, Maternity, Mobilization, Rapid Mobilization, ERACS
Adverse events following immunization (AEFIs) in health workers who receive COVID-19 vaccination at Academic Hospital Universitas Gadjah Mada, Yogyakarta Lestari, Ade Febrina; Sitaresmi, Mei Neni; Haspitaningrum, Anjarsari; Rachmasari, Kusuma Ayu; Wulandari, Ratih; Sari, Shinta Kusumalarna; Ridhayani, Firda
Indonesian Journal of Pharmacology and Therapy Vol 4 No 1 (2023)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.6860

Abstract

COVID-19 is a new viral infection that has become a global pandemic, resulting in extremely high mortality and morbidity rates worldwide, including in Indonesia. Vaccination is one of the strategies for preventing COVID-19 infection promoted by the World Health Organization (WHO) to reduce COVID-19 morbidity and mortality. The Indonesian government supports the implementation of vaccination and conducts mass vaccination as a strategy to overcome the pandemic in Indonesia. The high immunization coverage resulted in increased use of vaccines, and events following immunization (AEFI) also increased. Reports on follow-up AEFI are needed as government policy references and information for the public. This study aims to describe the following events after the COVID-19 vaccine immunization and the incidence of the infection post vaccination. The study design was a cross-sectional study using primary and secondary data. The data were analyzed descriptively and statistically using Chi Square method by identifying association between demographic data and AEFI incidence. A total 131 respondents were included. Most respondents experienced AEFI after giving the first (77.1%) or second (71.9%) vaccine with the Sinovac vaccine. However, all reported mild AEFI. Most reported AEFIs were pain (48.8% and 49.6%), hungry (37.4% and 10.0%), and drowsiness (32.1% and 23.7%) after the first and the second vaccine. In conclusion, the prevalence of AEFI in the first and the second dose of inactivated COVID-19 vaccine is higher than that reported in the clinical trial study although the all AEFIs are considered as mild.